%0 Journal Article
%T Should every patient with muscle-invasive bladder cancer receive neoadjuvant chemotherapy?
%A Arnulf Stenzl
%A Moritz Maas
%J Archive of "Translational Andrology and Urology".
%D 2019
%R 10.21037/tau.2019.03.03
%X The use of cisplatin-based neoadjuvant chemotherapy (NAC) for all patients with muscle-invasive bladder cancer (MIBC) is recommended by current guidelines (1,2). However, the study of Bhindi et al. suggest, that patients not responding to NAC show an inferior survival than a comparable control group (3). Furthermore, only 20¨C38% of the patients exposed towards NAC show a histopathological response (4). Taking these aspects and the known chemotherapy-related toxicity into consideration leads both, providers and patients, to the question whether the potential benefits of NAC outweigh its disadvantages
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642982/